Unibest

Pharmaceutical intermediates

Remibrutinib Intermediates

3 pharmaceutical intermediates for Remibrutinib. Indication: Chronic Urticaria; Multiple Sclerosis.

提交项目All intermediates

About Remibrutinib

Originator
Novartis Pharmaceuticals Corp
Indication
Chronic Urticaria; Multiple Sclerosis

Available intermediates

3 intermediates currently listed for Remibrutinib. Request specifications, documentation or a quotation for any item below.

Remibrutinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
5-Fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline1418128-33-2//
tert-butyl 2-(4-amino-6-chloropyrimidin-5-yloxy)ethylmethylcarbamate1787294-51-2//
4-cyclopropyl-2-fluoro-N-(5-fluoro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide1787294-47-6//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RepotrectinibResmetiromRevumenibRibociclib Succinate

Building toward Remibrutinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →